首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Human vaccines & immunotherapeutics

缩写:HUM VACC IMMUNOTHER

ISSN:2164-5515

e-ISSN:2164-554X

IF/分区:4.2/Q2

文章目录 更多期刊信息

共收录本刊相关文章索引7331
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Peter S Nyasulu,Jacques L Tamuzi,Chinwe Iwu-Jaja et al. Peter S Nyasulu et al.
Mapping current vaccinology courses is critical for identifying educational gaps, refining program content, and increasing international cooperation to achieve a competent and well-coordinated global vaccination effort. This scoping review ...
Yuechen Xu,Yu Xu,Zhisen Wang et al. Yuechen Xu et al.
Chimeric antigen receptor T cell (CAR-T) immunotherapy has achieved landmark success in hematologic malignancies and is being explored for breast cancer (BC) and other solid tumors, prompting research to improve efficacy and safety. We retr...
Mark Alexander Forsberg,Yago Nieto Mark Alexander Forsberg
NK cells have rapidly become a leading platform for cancer immunotherapy. Unlike T cells, NK cells recognize transformed cells through integrated signals from inhibitory and activating receptors, enabling allogeneic "off-the-shelf" therapie...
Omer Zaidi,Eun Hwa Choi,Margaret Ip et al. Omer Zaidi et al.
The purpose of this systematic review was to summarize the most recent national immunization programs (NIPs) for pneumococcal vaccinations among pediatric populations and changes in disease burden pre/post vaccination availability in 14 sel...
Yuanyuan Zhu,Jing Yu,Ran Hu et al. Yuanyuan Zhu et al.
China's immunization policy was updated in 2020, replacing the sequence of MR (at 8-12 months) and MMR (at 18-24 months) with a comprehensive two-dose MMR schedule.This study aims to evaluate the safety of this policy shift by comparing the...
Nina B Masters,Karen Gilbert Farrar,Duy Do et al. Nina B Masters et al.
The Shingrix vaccine has been recommended for immunocompetent adults aged ≥50 y since October 2017. It is important to assess recent trends and predictors of Shingrix vaccination among those newly eligible to evaluate acceptability, desira...
Supichcha Saithong,Eakachai Prompetchara,Chutitorn Ketloy et al. Supichcha Saithong et al.
Persistent infection with high-risk human papillomavirus (HPV) drives the development of cervical and other anogenital cancers, with limited therapeutic options for early-stage disease and precancerous lesions. There is a critical unmet nee...
Ana Luiza Bierrenbach,Paula Cristina Pungartnik,Rodrigo Gonçalves Queijo et al. Ana Luiza Bierrenbach et al.
Cervical cancer remains a leading cause of disease burden among women, despite being largely preventable. High-grade cervical intraepithelial neoplasia (CIN) is a key intermediate outcome for evaluating early population-level effects of HPV...
Honghao Wang,Shangying Hu,Meiwen Yuan et al. Honghao Wang et al.
Although human papillomavirus (HPV) infection constitutes a significant public health challenge, the HPV vaccination coverage remains suboptimal in China. Recent roll-out of new policies calls for an updated evaluation on the knowledge, att...